We are an innovative biopharmaceutical company developing next-generation therapeutics based on our proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Our initial focus is on developing a novel class of T cell engagers (TCEs), and our lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome (CRS), (ii) on-target, healthy tissue toxicities and (iii) poor pharmacokinetics (PK) leading to short half-life.

Our lead TRACTr product candidates are designed to target PSMA, EGFR, and TROP2. Each of these tumor targets are clinically validated and implicated in solid tumors with high prevalence, including metastatic castrate-resistant prostate cancer (mCRPC), colorectal cancer (CRC), squamous cell cancer of the head and neck (SCCHN), triple-negative breast cancer (TNBC), urothelial cancer (UC), and non-small cell lung cancer (NSCLC). We anticipate submitting Investigational New Drug applications (INDs) for at least two of these product candidates by the end of 2022.

(Note: Janux Therapeutics upsized its IPO at pricing on June 10, 2021, to 11.4 million shares, up from 9.5 million in the prospectus, at $17 – the top of its $15-to-$17 range – to raise $193.8 million.)